New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2013
10:07 EDTCELG, HK, OTEX, SWHC, MPC, VLO, ALJ, CVI, UNP, TIF, SPR, KSS, CF, SOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Celgene (CELG) upgraded to Buy from Neutral at UBS... CF Industries (CF) upgraded to Neutral from Sell at Goldman... Kohlís (KSS) upgraded to Buy from Neutral at BofA/Merrill... Spirit AeroSystems (SPR) upgraded to buy from Hold at Canaccord... Tiffany (TIF) upgraded to Conviction Buy from Neutral at Goldman... Union Pacific (UNP) upgraded to Strong Buy from Outperform at Raymond James... CVR Energy (CVI) upgraded to Neutral from Underperform at Macquarie... Alon USA Energy (ALJ) upgraded to Neutral from Underperform at Macquarie... Valero Energy (VLO) upgraded to Outperform from Neutral at Macquarie... Marathon Petroleum (MPC) upgraded to Outperform from Neutral at Macquarie... Smith & Wesson (SWHC) upgraded to Buy from Hold at Lake Street... Open Text (OTEX) upgraded to Neutral from Negative at Susquehanna... Sprint (S) upgraded to Buy from Neutral at Nomura... Halcon Resources (HK) upgraded at Morgan Stanley.
News For CELG;CF;KSS;SPR;TIF;UNP;CVI;ALJ;VLO;MPC;SWHC;OTEX;HK;S From The Last 14 Days
Check below for free stories on CELG;CF;KSS;SPR;TIF;UNP;CVI;ALJ;VLO;MPC;SWHC;OTEX;HK;S the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 10, 2014
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
06:20 EDTCFCF Industries downgraded to Equalweight from Overweight at Barclays
Barclays downgraded CF Industries based on relative valuation. Price target remains $267.
06:03 EDTHKStocks with implied volatility movement; KOG HK
Subscribe for More Information
April 9, 2014
16:34 EDTKSSAbercrombie & Fitch names Joanne Crevoiserat CFO
Subscribe for More Information
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
12:04 EDTCFU.S. corn exports projected to increase 125M bushels
Subscribe for More Information
11:15 EDTST-Mobile unveils $40 monthly price plan called 'Simple Starter'
Subscribe for More Information
09:20 EDTTIFBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2014
07:52 EDTVLO, ALJRefiners 2014 EPS estimates raised at Wells Fargo
Wells Fargo significantly raised its 2014 EPS estimates for Alon USA (ALJ), PBF Energy (PBF), Valero (VLO), and Western Refining (WNR) . The firm thinks that the sector is benefiting from better crack spreads and refining utilization so far in Q2, while U.S. exports of refined products jumped 21% year-over-year last quarter. Wells keeps Outperform ratings on PBF and Valero, and Market Perform ratings on Alon USA and Western Refining.
April 4, 2014
12:13 EDTSSprint launches promotion, offering $650 for customers to switch, BGR reports
Sprint has begun a promotion that will offer people up to $650 to make the switch to their company, reports BGR. Through a forum member on Sprint's fan site S4GRU, the company launched a limited promotion to reimburse new customers up to $350 in early termination fees, as well as a service credit of up to $300 when they trade in their old phones. Reference Link
11:02 EDTSSoftbank said to eye possible M&A opportunities in Europe, Forbes says
Subscribe for More Information
10:45 EDTCELGMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
08:47 EDTSLenovo, IBM deal investigated by U.S. over Pentagon servers, Bloomberg says
Subscribe for More Information
08:07 EDTSRegulators 'increasingly open' to Sprint, T-Mobile merger, says FBR Capital
Subscribe for More Information
06:49 EDTCELGMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Subscribe for More Information
April 3, 2014
12:20 EDTSGoogle considers wireless service in Fiber markets, The Information says
Subscribe for More Information
10:00 EDTCFOn The Fly: Analyst Downgrade Summary
BB&T (BBT) downgraded to Outperform from Strong Buy at Raymond James... Broadcom (BRCM) downgraded to Neutral from Overweight at Piper Jaffray... CF Industries (CF) downgraded to Neutral from Buy at Citigroup... CSX (CSX) downgraded to Equalweight from Overweight at Barclays... Cheniere Energy (LNG) downgraded to Neutral from Outperform at Credit Suisse... Citigroup (C) downgraded to Neutral from Buy at Sterne Agee... Deutsche Bank (DB) downgraded to Neutral from Overweight at JPMorgan... G&K Services (GK) downgraded to Neutral from Outperform at RW Baird... Marcus (MCS) downgraded to Neutral from Buy at B. Riley... National Retail Properties (NNN) downgraded to Sell from Neutral at UBS... Norfolk Southern (NSC) downgraded to Neutral from Overweight at Atlantic Equities... Orion Energy (OESX) downgraded to Hold from Buy at Ascendiant... VIVUS (VVUS) downgraded to Underweight from Neutral at Piper Jaffray... Liquidity Services (LQDT) downgraded to Neutral from Outperform at RW Baird... Shaw Communications (SJR) downgraded to Sector Performer from Outperformer at CIBC... USG (USG) downgraded to Neutral from Outperform at Macquarie... Level 3 (LVLT) downgraded to Hold from Buy at Gabelli... U.S. Bancorp (USB) downgraded to Neutral from Conviction Buy at Goldman... Extra Space Storage (EXR) downgraded to Buy from Conviction Buy at Goldman... First Republic Bank (FRC) downgraded to Buy from Conviction Buy at Goldman... TELUS (TU) downgraded to Neutral from Outperform at Macquarie.
06:28 EDTCELGAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
06:22 EDTCFCF Industries downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use